The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome
| Autor: | Adrian Wlodarczak, Jan Jakub Kulczycki, Mateusz Barycki, Marek Szudrowicz, Maciej Lesiak, Adrian Doroszko, Magdalena Łanocha, Alicja Gosiewska, Piotr Rola |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Acute coronary syndrome medicine.medical_treatment 030204 cardiovascular system & hematology Article 03 medical and health sciences acute coronary syndrome (ACS) 0302 clinical medicine Restenosis coronary artery disease (CAD) Internal medicine Diabetes mellitus diabetes mellitus (DM) medicine 030212 general & internal medicine Myocardial infarction magnesium bioresorbable scaffold (BRS) business.industry Magmaris Percutaneous coronary intervention General Medicine medicine.disease Thrombosis Increased risk Conventional PCI Cardiology Medicine percutaneous coronary intervention (PCI) business |
| Zdroj: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 10, Iss 3166, p 3166 (2021) Volume 10 Issue 14 |
| ISSN: | 2077-0383 |
| Popis: | Background: Diabetes mellitus (DM) is one of the major risk factors contributing to Acute Coronary Syndromes (ACS) and is associated with an increased risk of adverse clinical outcomes following percutaneous coronary intervention (PCI), even when the second generation of drug-eluting stents (DES) is used. In order to overcome the disadvantages of permanent caging of a vessel with metallic DES, bioresorbable scaffold (BRS) technology has been recently developed. However, the prognosis of patients with DM and ACS treated with PCI via subsequent implantation of Magmaris (Biotronik, Berlin, Germany)—a novel magnesium-bioresorbable scaffold—is poorly investigated. Methods: A total of 193 consecutive subjects with non-ST elevation acute coronary syndrome (NSTE-ACS) who, from October 2016 to March 2020, received one or more Magmaris scaffolds were enrolled in this study. The diabetic group was compared with non-diabetic subjects. Results: There were no significant differences in the occurrence of primary endpoints (cardiovascular death, myocardial infarction, and in-stent thrombosis) and principal secondary endpoints (target-lesion failure, scaffold restenosis, death from any reason, and other cardiovascular events) between the two compared groups in a 1-year follow-up period. Conclusions: The early 1-year-outcome of magnesium bioresorbable scaffold (Magmaris) seems to be favorable and suggests that this novel BRS is safe and effective in subjects with NSTE-ACS and co-existing DM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|